VB10.16 + Pembrolizumab
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Trial Timeline
Dec 19, 2023 → Jan 1, 2028
NCT ID
NCT06016920About VB10.16 + Pembrolizumab
VB10.16 + Pembrolizumab is a phase 1/2 stage product being developed by Merck for HPV Positive Oropharyngeal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06016920. Target conditions include HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06016920 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in HPV Positive Oropharyngeal Squamous Cell Carcinoma